Incyte
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
Study of the JAK Inhibitor Ruxolitinib Administered Orally to Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)
- First Posted Date
- 2011-03-17
- Last Posted Date
- 2022-03-09
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 69
- Registration Number
- NCT01317875
Safety and Efficacy of INCB007839 With Trastuzumab and Vinorelbine in Patients With Metastatic HER2+ Breast Cancer
Phase 1
Terminated
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2010-12-06
- Last Posted Date
- 2012-01-25
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 20
- Registration Number
- NCT01254136
Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)
Phase 3
Completed
- Conditions
- Polycythemia Vera
- Interventions
- Other: Best Available Therapy (BAT)
- First Posted Date
- 2010-11-19
- Last Posted Date
- 2019-03-06
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 222
- Registration Number
- NCT01243944
A Dose-escalation Study in Subjects With Advanced Malignancies
- First Posted Date
- 2010-09-06
- Last Posted Date
- 2018-01-17
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 52
- Registration Number
- NCT01195311
A Dose-escalation Study in Subjects With Advanced Malignancies
- First Posted Date
- 2010-02-22
- Last Posted Date
- 2017-11-22
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 45
- Registration Number
- NCT01072266
COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial
Phase 3
Completed
- Conditions
- MPN (Myeloproliferative Neoplasms)
- Interventions
- Drug: Placebo
- First Posted Date
- 2009-08-06
- Last Posted Date
- 2018-03-12
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 309
- Registration Number
- NCT00952289
INCB028050 Compared to Background Therapy in Patients With Active Rheumatoid Arthritis (RA) With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs
- First Posted Date
- 2009-05-15
- Last Posted Date
- 2018-09-04
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 127
- Registration Number
- NCT00902486
Open Label Trial of INCB07839 to Determine Effect and Safety of INCB007839 Plus Trastuzumab in HER2 Positive Metastatic Breast Cancer
Phase 1
Terminated
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2009-03-18
- Last Posted Date
- 2018-01-18
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 68
- Registration Number
- NCT00864175
A Study of Ruxolitinib Phosphate Cream When Applied to Patients With Plaque Psoriasis
Phase 2
Completed
- Conditions
- Psoriasis
- Interventions
- First Posted Date
- 2009-01-12
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 29
- Registration Number
- NCT00820950
Open-Label Study to Assess the Safety/Tolerability in Patients With Solid Tumors
- First Posted Date
- 2009-01-12
- Last Posted Date
- 2018-01-17
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 41
- Registration Number
- NCT00820560
© Copyright 2025. All Rights Reserved by MedPath